NEWS: This week, Swing Therapeutics received De Novo marketing authorization by the FDA for Stanza, the first prescription digital therapeutic for treating #fibromyalgia symptoms.
Learn more about this milestone: swingtherapeutics.com/swing-…
Stanza, the first prescription digital therapy for #fibromyalgia patients in the U.S., is now commercially available.
Read more from CEO @mikerosenbluth swingtherapeutics.com/introd…
📰 NEWS: Today we announced the close of our Series A funding round and the launch of our PROSPER-FM pivotal Phase 3 clinical trial for our digital therapeutic for the treatment of #fibromyalgia. Learn more: businesswire.com/news/home/2…
#FibroAwareness #DigitalHealth #HealthTech
We're inspired every day by people facing chronic illness and pain. We’re committed to developing cutting-edge, accessible digital therapies to help people with #fibromyalgia live their best lives. Learn more: swingtherapeutics.com/for-pa…
#FibromyalgiaAwarenessDay #FibroAwarenessDay
Read about us in an article by @emmakbetuel at @TechCrunch: tcrn.ch/3iXEP1n. It covers our recent announcements including FDA breakthrough designation for our first digital therapeutic in development for the management of fibromyalgia & the launch of our real-world study.
The Swing team works each day to develop innovative and impactful digital therapeutics to address the real unmet needs of people with underserved chronic conditions, so they can live their best lives. Learn more about our developments thus far: bwnews.pr/3CFCPCA
